Study S002033

Intravenous Exenatide (Byetta®) Versus Insulin for Perioperative Glycemic Control in Cardiac Surgery: the Open-labeled Randomized Phase II/III ExStress Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01969149
Acronym: ExSTRESS
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 110
Start: 2015-01
Primary completion: 2015-12
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Conditions: Stress Hyperglycemia
Interventions: DRUG:Exenatide; DRUG:Insulin
Results posted: FALSE

Registered primary outcomes

Percentage of patients spending more than 50 % of the time in the glycemic target range (100 to 140 mg/dl) [48 hours]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021932	Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial. Besch G, Cardiovascular diabetology	2018	Randomized trial	PMID 30384842 DOI	cites ClinicalTrials.gov:NCT01969149; registry reference DERIVED:30384842